NeuralSense
NeuralSense Raises $200M Series C to Transform Biotech
NeuralSense Raises $200M Series C in Latest Funding Round
NeuralSense has successfully closed a $200M Series C funding round, marking a significant milestone in the company's growth trajectory. The round was led by Founders Fund, with participation from General Catalyst.
Company Overview
Founded in 2021 and headquartered in Austin, TX, NeuralSense has established itself in the Biotech space. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses
With a current valuation of $800M, the company has demonstrated strong market traction and investor confidence.
Investment Details
- Amount Raised: $200M Series C
- Valuation: $800M
- Lead Investor: Founders Fund
Future Outlook
As NeuralSense moves forward with its expanded funding, the company is well-positioned to capitalize on market opportunities and drive innovation in the biotech space.
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started